{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:26:35Z","timestamp":1789014395224,"version":"build-2803163510"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/mop.0b013e3282f424b0","type":"journal-article","created":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T08:01:14Z","timestamp":1200038474000},"page":"17-22","source":"Crossref","is-referenced-by-count":36,"title":["The efficacy of rituximab in high-grade pediatric B-cell lymphoma\/leukemia: a review of available evidence"],"prefix":"10.1097","volume":"20","author":[{"given":"Dina","family":"Attias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-4-20210206","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00277-003-0758-2","article-title":"Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma","volume":"83","author":"Yokohama","year":"2004","journal-title":"Ann Hematol"},{"key":"R6-4-20210206","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2006.06.008","article-title":"Novel antibody-based therapy for acute lymphoblastic leukaemia","volume":"19","author":"G\u00f6kbuget","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"A2736","DOI":"10.1182\/blood.V108.11.2736.2736","article-title":"Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome [abstract]","volume":"108","author":"Dunleavy","year":"2006","journal-title":"Blood"},{"key":"R9-4-20210206","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/pbc.20957","article-title":"Rituximab in a child with relapsed Burkitt lymphoma","volume":"49","author":"Bay","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08880010500313280","article-title":"Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma","volume":"23","author":"Imamura","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.mph.0000158089.92165.a8","article-title":"Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma","volume":"27","author":"Jetsrisuparb","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R13-4-20210206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/08880010500313298","article-title":"Refractoriness to rituximab monotherapy in a child with relapsed\/refractory Burkitt non Hodgkin lymphoma","volume":"23","author":"Okur","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"key":"R14-4-20210206","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00043426-200304000-00013","article-title":"Induction of long-term remission of a relapsed childhood B acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation","volume":"25","author":"Corbacioglu","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2004.04925.x","article-title":"Rituximab in three children with relapsed\/refractory B-cell acute lymphoblastic leukaemia\/Burkitt non-Hodgkin's lymphoma","volume":"125","author":"de Vries","year":"2004","journal-title":"Br J Haematol"},{"key":"R16-4-20210206","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/08880010390203125","article-title":"Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl","volume":"20","author":"Culic","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/10428190601142831","article-title":"Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child","volume":"48","author":"Akyuz","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R18-4-20210206","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mpo.1335","article-title":"Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission","volume":"38","author":"Ozsahin","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"R19-4-20210206","first-page":"272","article-title":"Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia","volume":"91","author":"Claviez","year":"2006","journal-title":"Haematologica"},{"issue":"Suppl","key":"R20-4-20210206","first-page":"ECR24","article-title":"Optic nerve relapse in a child with common acute lymphoblastic leukemia treated with systemic anti CD-20 (rituximab).","volume":"90","author":"Kraal","year":"2005","journal-title":"Haematologica"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/08880010600957259","article-title":"Anti CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocytic predominant Hodgkin lymphoma in an 10-year-old girl","volume":"23","author":"Culic","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B-cell in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1309\/438N-E0FH-A5PR-XCAC","article-title":"Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia","volume":"116","author":"Huh","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4049\/jimmunol.178.4.2287","article-title":"Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis","volume":"178","author":"Stel","year":"2007","journal-title":"J Immunol"},{"key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2006.12.038","article-title":"Treatment with rituximab in benign and malignant hematologic disorders in children","volume":"150","author":"Giulino","year":"2007","journal-title":"J Pediatr"},{"key":"R26-4-20210206","first-page":"314","article-title":"B-cell non-Hodgkin's lymphoma in children and adolescence: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report","volume":"1","author":"Perkins","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"R28-4-20210206","first-page":"351","article-title":"Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature","volume":"26","author":"Pels","year":"2003","journal-title":"Onkologie"},{"key":"R29-4-20210206","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1019999830455","article-title":"Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab","volume":"59","author":"Pels","year":"2002","journal-title":"J Neurooncol"},{"key":"R30-4-20210206","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3171\/jns.1986.65.2.0194","article-title":"Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin. Implications for monclonal antibody therapy","volume":"65","author":"Neuwelt","year":"1986","journal-title":"J Neurosurg"},{"key":"R31-4-20210206","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-006-9217-y","article-title":"Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma","volume":"81","author":"Antonini","year":"2007","journal-title":"J Neurooncol"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"key":"R33-4-20210206","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R34-4-20210206","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B lymphocyte depletion therapy with rituximab in rheumatoid arthritis","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"R35-4-20210206","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R36-4-20210206","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"R37-4-20210206","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"6 Suppl 12","key":"R38-4-20210206","first-page":"37","article-title":"Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma","volume":"27","author":"McLaughlin","year":"2000","journal-title":"Semin Oncol"},{"key":"R39-4-20210206","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"R40-4-20210206","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B postchemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R41-4-20210206","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/07357900600815232","article-title":"Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis","volume":"24","author":"Coiffier","year":"2006","journal-title":"Cancer Invest"},{"key":"R42-4-20210206","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","article-title":"Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses","volume":"4","author":"Agarwal","year":"2004","journal-title":"Am J Transplant"},{"key":"R43-4-20210206","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"R44-4-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1397-3142.2003.00135.x","article-title":"The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation","volume":"8","author":"Pescovits","year":"2004","journal-title":"Pediatr Transplant"},{"issue":"1 Suppl 2","key":"R45-4-20210206","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/sonc.2002.30151","article-title":"The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R","volume":"29","author":"Wilson","year":"2002","journal-title":"Semin Oncol"},{"key":"R46-4-20210206","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (minT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncology"},{"issue":"Suppl","key":"R47-4-20210206","first-page":"5985","article-title":"Dose-escalated CHOP+etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL","volume":"23","author":"Glass","year":"2005","journal-title":"J Clin Oncol"},{"key":"R48-4-20210206","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"R49-4-20210206","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pbc.21166","article-title":"Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors","volume":"49","author":"Franchini","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R50-4-20210206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2141.2001.03041.x","article-title":"Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children","volume":"115","author":"Faye","year":"2001","journal-title":"Br J Haematol"},{"key":"R51-4-20210206","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pbc.20121","article-title":"Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group","volume":"44","author":"Attarbaschi","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R52-4-20210206","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","article-title":"Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912","volume":"19","author":"Kobrinsky","year":"2001","journal-title":"J Clin Oncol"},{"key":"R53-4-20210206","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.V81.8.2003.2003","article-title":"Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'oncologie Pediatrique","volume":"81","author":"Philip","year":"1993","journal-title":"Blood"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e3282f424b0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:10Z","timestamp":1620963430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-200802000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e3282f424b0","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}